Canal Capital Management LLC raised its stake in shares of Johnson & Johnson (NYSE:JNJ) by 15.7% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 16,938 shares of the company’s stock after buying an additional 2,304 shares during the period. Johnson & Johnson comprises about 1.3% of Canal Capital Management LLC’s investment portfolio, making the stock its 20th biggest holding. Canal Capital Management LLC’s holdings in Johnson & Johnson were worth $2,367,000 as of its most recent filing with the Securities & Exchange Commission.
Other large investors also recently modified their holdings of the company. Harding Loevner LP bought a new position in Johnson & Johnson in the 2nd quarter worth $106,000. IHT Wealth Management LLC raised its holdings in Johnson & Johnson by 46.4% in the 2nd quarter. IHT Wealth Management LLC now owns 10,942 shares of the company’s stock worth $122,000 after acquiring an additional 3,467 shares during the period. Mountain Capital Investment Advisors Inc bought a new position in Johnson & Johnson in the 2nd quarter worth $124,000. Cerebellum GP LLC bought a new position in Johnson & Johnson in the 4th quarter worth $166,000. Finally, Lenox Wealth Management Inc. raised its holdings in Johnson & Johnson by 1.7% in the 2nd quarter. Lenox Wealth Management Inc. now owns 1,457 shares of the company’s stock worth $193,000 after acquiring an additional 24 shares during the period. 67.23% of the stock is owned by institutional investors.
Several research analysts recently commented on JNJ shares. Vetr upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating and set a $150.89 target price on the stock in a report on Thursday, January 11th. Royal Bank of Canada reiterated a “buy” rating on shares of Johnson & Johnson in a report on Tuesday, January 9th. Jefferies Group set a $165.00 target price on shares of Johnson & Johnson and gave the stock a “buy” rating in a report on Monday, February 26th. Zacks Investment Research upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating and set a $143.00 target price on the stock in a report on Wednesday, March 28th. Finally, TheStreet downgraded shares of Johnson & Johnson from an “a” rating to a “c+” rating in a report on Monday, March 26th. Five equities research analysts have rated the stock with a sell rating, nine have given a hold rating and eight have given a buy rating to the company. The company has an average rating of “Hold” and a consensus price target of $144.03.
In other news, VP Paulus Stoffels sold 155,342 shares of the business’s stock in a transaction dated Thursday, February 15th. The shares were sold at an average price of $129.86, for a total transaction of $20,172,712.12. Following the transaction, the vice president now owns 357,906 shares in the company, valued at approximately $46,477,673.16. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Insiders own 0.22% of the company’s stock.
NYSE:JNJ opened at $131.76 on Tuesday. Johnson & Johnson has a 52-week low of $120.95 and a 52-week high of $148.32. The company has a current ratio of 1.41, a quick ratio of 1.12 and a debt-to-equity ratio of 0.51. The stock has a market cap of $350,440.66, a PE ratio of 18.05, a P/E/G ratio of 2.08 and a beta of 0.74.
Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Tuesday, January 23rd. The company reported $1.74 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.72 by $0.02. Johnson & Johnson had a net margin of 1.70% and a return on equity of 29.00%. The company had revenue of $20.20 billion for the quarter, compared to the consensus estimate of $20.08 billion. During the same quarter in the previous year, the firm posted $1.58 EPS. The business’s revenue was up 11.5% compared to the same quarter last year. research analysts expect that Johnson & Johnson will post 8.11 earnings per share for the current year.
COPYRIGHT VIOLATION WARNING: This news story was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this news story on another publication, it was illegally stolen and reposted in violation of international copyright & trademark laws. The correct version of this news story can be viewed at https://www.dispatchtribunal.com/2018/04/17/canal-capital-management-llc-raises-holdings-in-johnson-johnson-jnj.html.
Johnson & Johnson Company Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.